Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211
Giuseppe Fallara(Istituti di Ricovero e Cura a Carattere Scientifico), Alberto Martini(The University of Texas MD Anderson Cancer Center), Bernard Malavaud(Institut universitaire du cancer de Toulouse Oncopole), Daniele Robesti(Vita-Salute San Raffaele University), Sharada Mokkapati(The University of Texas MD Anderson Cancer Center), Côme Tholomier(The University of Texas MD Anderson Cancer Center), Francesco Montorsi(Vita-Salute San Raffaele University), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Pavlos Msaouel(The University of Texas MD Anderson Cancer Center), Federico Belladelli(IRCCS Ospedale San Raffaele)
Cited by 3
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease
|Annals of the Rheumatic Diseases|2001|287